NRX Pharmaceuticals, Inc. (NRXP): Total Assets
$12.96M
As of 2025-12-31
$34.16M
As of 2026-06-30
-20.5%
3-year compound annual growth
+34.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.96M | +254.9% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $3.65M | -50.1% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $7.32M | -71.7% | 2025-03-14, Balance as of period end |
| 2022-12-31 | $25.82M | -21.1% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $32.73M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | $2.94M | -90.8% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $32.07M | -54.7% | 2021-05-14, Balance as of period end |
| 2018-12-31 | $70.80M | +1.8% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $69.57M | n/a | 2019-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $12.96M | +254.9% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.93M | +9.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $81.29M | +204.1% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $7.02M | -35.2% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $58.62M | +60.0% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $10.26M | -59.9% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $28.71M | +0.4% |
Compare NRXP, ATXI, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗